$ABCL

AbCellera Biologics (ABCL) stock rose 121% in 3 months, outpacing its industry. The surge was driven by positive phase II data for ABCL635, a treatment for menopause symptoms, and new partnerships. The study met primary endpoints, showing significant reductions in hot flash frequency and severity. Additional data is expected in October. The company also reported strong financial stability and investor confidence.

AbCellera Biologics (ABCL) announced a Phase 2 data presentation for its menopause drug ABCL635. The stock has seen significant gains, with a 128.39% return over 90 days and 268.22% year-to-date. The company is valued at $12.63, with a fair value estimate of $14.63. AbCellera has $630 million in liquidity and aims to complete clinical manufacturing by 2025, which could improve margins. However, risks include potential trial failures and high R&D spending.

AbCellera (ABCL) and Recursion (RXRX) are AI-driven biotechs with divergent profiles. ABCL's stock surged 169.7% in a year but is overvalued by 44.4% according to fair value estimates, while RXRX fell 28.2% and is near fair value. ABCL's revenue is volatile, and RXRX's losses are accelerating. Analysts see 17.8% upside for ABCL and 97.7% for RXRX. Technical indicators suggest ABCL is overbought, while RXRX is range-bound.

MediciNova (MNOV) +36%, AbCellera (ABCL) +9%, Parabilis (PBLS) +10%, Haemonetics (HAE), and NeoGenomics (NEO) reached 52-week highs on Sept 17, 2026. MNOV's MN-166 is in Phase 3 trials. ABCL's ABCL635 met primary endpoint in Phase 2. PBLS raised $770.5M in IPO. HAE reported 5.6% revenue growth. NEO's RaDaR ST test got Medicare/Medicaid coverage, revenues up 11%.

AbCellera Biologics (NASDAQ: ABCL) will present Phase 2 clinical data for ABCL635 at the 20th World Congress on Menopause. The company's P/S ratio is 52.59, significantly higher than its historical median of 20.67, indicating high growth expectations. Insiders have bought $2.7 million in shares, while some institutional investors have trimmed holdings. The GF Value™ metric suggests the stock is 171.0% overvalued at $11.57 per share.

AbCellera (Nasdaq: ABCL) will present Phase 2 data for its drug ABCL635 at the IMS World Congress on Menopause 2026. The trial evaluates the safety and efficacy of ABCL635, a non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) in postmenopausal women. The presentation is scheduled for October 1, 2026, in Rio de Janeiro, Brazil.

Sellas Life Sciences (SLS), Moderna (MRNA), and AbCellera Biologics (ABCL) reached 52-week highs, with SLS up 17%, MRNA up 12%, and ABCL up 10%. SLS's rise was driven by acquisition speculation and AML trial updates, MRNA by its Science Day presentation, and ABCL by a collaboration with Jazz Pharmaceuticals. Year-to-date, SLS is up 228%, MRNA 128%, and ABCL 115%.

Trading alerts issued for AbCellera Biologics (ABCL) on NASDAQ. A covered call strategy is recommended for half of the long position. The price target is set at $20. ABCL's stock has recently spiked due to positive phase 2 data for ABCL635.

AbCellera Biologics (ABCL) shares rose 9% on Friday and 4% after hours, marking an 18% weekly gain. Investors anticipate Q1 2026 earnings and clinical data for ABCL635, a non-hormonal menopause treatment. Baker Bros. increased its stake to 10.8%. Analysts expect $5.84M revenue and a $0.19 loss per share. The average price target is $9.14, with 8 of 9 analysts rating it 'Buy' or higher.

AbCellera (ABCL) reported Q2 2026 revenue of $4.1M, down from $17.1M YoY, with a net loss of $55.4M. The company advanced its pipeline, including ABCL635, which met primary endpoints in a Phase 2 study, and announced collaborations with Jazz and Vertex Pharmaceuticals, receiving upfront payments totaling $112M. ABCL ended the quarter with $675M in liquidity. Shares are up 16.78% to $12.40.